1
/
of
1
Gemtero (Gemcitabine)
Gemtero (Gemcitabine)
Regular price
₱2,340.00 PHP
Regular price
Sale price
₱2,340.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Gemtero (Gemcitabine) – Chemotherapy Antimetabolite for Advanced Cancer Treatment
Gemtero contains gemcitabine, a nucleoside analog antimetabolite chemotherapy agent used in the treatment of multiple solid tumors. This intravenous medication works by incorporating into DNA during cell replication, causing chain termination and apoptosis, making it effective for inhibiting rapidly dividing cancer cells while maintaining a relatively favorable toxicity profile compared to conventional chemotherapy regimens.
Gemcitabine is indicated as a first-line and combination therapy option for pancreatic cancer, the primary malignancy for which it demonstrates significant clinical benefit. Additional approved uses include non-small cell lung cancer (NSCLC), where it is often combined with cisplatin or other platinum agents, breast cancer (frequently administered with paclitaxel), ovarian cancer (commonly paired with carboplatin), and urothelial bladder cancer. The drug's mechanism of action as an antimetabolite makes it suitable for patients requiring systemic chemotherapy where traditional cytotoxic agents may be contraindicated or have demonstrated inadequate efficacy.
Gemtero is administered exclusively via intravenous infusion under medical supervision in clinical or hospital settings. Dosing protocols are individualized based on patient factors including renal function, hepatic status, bone marrow reserve, and concurrent medications. Healthcare providers adjust dosage schedules and intervals according to hematologic tolerance, performance status, and response to therapy.
Important contraindications include documented hypersensitivity to gemcitabine or excipients, severe myelosuppression with critically low blood counts, and pregnancy or lactation due to embryofetal toxicity and unknown concentrations in breast milk. Caution is advised in patients with hepatic or renal impairment, those with recent radiotherapy (elevated risk of radiation recall phenomena), and individuals on concurrent medications affecting bone marrow function.
Gemtero requires prescription authorization and administration exclusively under oncology specialist supervision. Do not self-administer or discontinue without consulting your treating physician. Comprehensive medical evaluation and informed consent are mandatory prior to initiating gemcitabine therapy.
Gemtero contains gemcitabine, a nucleoside analog antimetabolite chemotherapy agent used in the treatment of multiple solid tumors. This intravenous medication works by incorporating into DNA during cell replication, causing chain termination and apoptosis, making it effective for inhibiting rapidly dividing cancer cells while maintaining a relatively favorable toxicity profile compared to conventional chemotherapy regimens.
Gemcitabine is indicated as a first-line and combination therapy option for pancreatic cancer, the primary malignancy for which it demonstrates significant clinical benefit. Additional approved uses include non-small cell lung cancer (NSCLC), where it is often combined with cisplatin or other platinum agents, breast cancer (frequently administered with paclitaxel), ovarian cancer (commonly paired with carboplatin), and urothelial bladder cancer. The drug's mechanism of action as an antimetabolite makes it suitable for patients requiring systemic chemotherapy where traditional cytotoxic agents may be contraindicated or have demonstrated inadequate efficacy.
Gemtero is administered exclusively via intravenous infusion under medical supervision in clinical or hospital settings. Dosing protocols are individualized based on patient factors including renal function, hepatic status, bone marrow reserve, and concurrent medications. Healthcare providers adjust dosage schedules and intervals according to hematologic tolerance, performance status, and response to therapy.
Important contraindications include documented hypersensitivity to gemcitabine or excipients, severe myelosuppression with critically low blood counts, and pregnancy or lactation due to embryofetal toxicity and unknown concentrations in breast milk. Caution is advised in patients with hepatic or renal impairment, those with recent radiotherapy (elevated risk of radiation recall phenomena), and individuals on concurrent medications affecting bone marrow function.
Gemtero requires prescription authorization and administration exclusively under oncology specialist supervision. Do not self-administer or discontinue without consulting your treating physician. Comprehensive medical evaluation and informed consent are mandatory prior to initiating gemcitabine therapy.
Share
